{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-158454","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2025-07-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.307421+00:00","generated_at":"2026-05-18T06:36:10.961751+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Corcept submits NDA for relacorilant as treatment for platinum-resistant ovarian cancer","bullets":["NDA submitted to FDA for relacorilant plus nab-paclitaxel, based on Phase 3 ROSELLA and Phase 2 trials.","Improved progression-free and overall survival vs nab-paclitaxel monotherapy; no biomarker selection needed.","Relacorilant well-tolerated; adverse events similar to monotherapy, no increased safety burden.","CEO notes this is Corcept's second NDA before FDA; relacorilant also under review for hypercortisolism.","Company preparing launch once approved; oncology and endocrinology units in place."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-158454","json":"https://secwatch.observer/filing/0001193125-25-158454.json","markdown":"https://secwatch.observer/filing/0001193125-25-158454.md","text":"https://secwatch.observer/filing/0001193125-25-158454.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000119312525158454/0001193125-25-158454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000119312525158454/d940113d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:36:10.961751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}